1 / 9

Molecular pathways for formation of eicosanoids and prostanoids

Molecular pathways for formation of eicosanoids and prostanoids. E.M. Antman, Circulation 2005; 112: 759-770. The 9 chemical groupings of NSAIDs are shown, along with key compounds in each class. Relative degree of COX-1 vs COX-2 selectivity is shown at the bottom of the figure.

howard-camacho
Télécharger la présentation

Molecular pathways for formation of eicosanoids and prostanoids

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular pathways for formation of eicosanoids and prostanoids E.M. Antman, Circulation 2005; 112: 759-770

  2. The 9 chemical groupings of NSAIDs are shown, along with key compounds in each class. Relative degree of COX-1 vs COX-2 selectivity is shown at the bottom of the figure E.M. Antman, Circulation 2005; 112: 759-770

  3. Comparison of COX-1 and COX-2 Enzymes E.M. Antman, Circulation 2005; 112: 759-770

  4. Structural determinants of inhibition of arachidonic acid binding to COXs E.M. Antman, Circulation 2005; 112: 759-770

  5. Consequences of COX inhibition for prostacyclin and thromboxane A2 production in normal and atherosclerotic arteries Endothelial cells are shown as a source of prostacyclin (PGI2) and platelets as a source of thromboxane A2 (TxA2) E.M. Antman, Circulation 2005; 112: 759-770

  6. Relationships between vascular eicosanoids and NO under normal conditions (A) and in inflammatory states (B) E.M. Antman, Circulation 2005; 112: 759-770

  7. Biostatistical considerations in a trial of a coxib vs placebo. Left, Main findings of the APC trialRight, A 2x2 table is used to arrange the data for the calculation of statistical tests of treatment effect E.M. Antman, Circulation 2005; 112: 759-770

  8. Detection of harm with coxibs. Factors related to trial design (top) and to the patient and drug being investigated (bottom) are shown E.M. Antman, Circulation 2005; 112: 759-770

  9. Number needed to harm E.M. Antman, Circulation 2005; 112: 759-770

More Related